5 October 2022 - NICE has published evidence based recommendations on the use of azacitidine for the maintenance treatment of adults with acute myeloid leukaemia after induction therapy.

Oral azacitidine is recommended as an option for the maintenance treatment of adults with acute myeloid leukaemia who:

• Are in complete remission, or complete remission with incomplete blood count recovery, after induction therapy with or without consolidation treatment
• Cannot have or do not want a haematopoietic stem cell transplant

It is recommended only if Celgene provides oral azacitidine according to the commercial arrangement.

Read NICE technology appraisal guidance